News & Updates

Multidisciplinary treatment works well for functional movement disorder

Combined physiotherapy and cognitive behavioural therapy (CBT) help produce improvements in functional movement disorder (FMD) symptoms and the physical aspects of the patients’ quality of life, as shown in a study.

Early intervention program cuts suicide, self-harm rates in schizophrenia

Among patients with first-episode schizophrenia, an extended early intervention service may lower the incidence of suicide and self-harm, according to a study.

Asian patients with pretreated chronic GVHD respond well with belumosudil

The selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor belumosudil mesylate appears to induce durable responses in Japanese patients with steroid-dependent/resistant chronic graft-versus-host disease (cGVHD) when used in the second or subsequent line of therapy, according to the results of a single-arm phase III study.

High olive oil intake helps promote longer life

Regular consumption of olive oil may provide protective benefits against cancer, cardiovascular, and all-cause mortality, independent of overall diet quality, suggests a study.

Sugar-sweetened beverage intake ups risk of AF

Consumption of sugar-sweetened beverages (SSBs) appears to induce atrial fibrillation (AF), while drinking pure fruit juice (PFJ) may help prevent the incidence of angina, suggests a recent study.

SG study underscores use of germline testing to guide cancer therapeutics

A study conducted at the Cancer Genetics Clinic of the National University Cancer Institute, Singapore underlines the use of germline genetic testing in guiding therapeutic decisions in individuals with advanced cancers.

Protein intake confers survival benefits for older adults with CKD

Older adults with chronic kidney disease (CKD) who consume high amounts of total, animal, and plant protein appear to have lower mortality, according to a study.

mPFS approaches 4 years with 1L durvalumab- and olaparib-incorporating 5-drug combo in aEOC

In patients with HRD+ advanced epithelial OC harbouring BRCA wild-type tumours, integrating durvalumab induction and durvalumab plus olaparib maintenance into 1L bevacizumab-containing chemotherapy significantly extends PFS and PFS2, suggest updated results from the DUO-O trial.